Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of...

Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...

On June 14, 2024, Alvotech filed information on Form 6-K with the U.S. Securities and Exchange Commission, pertaining to an Open Market Sale Agreement with Jefferies LLC, an accompanying Prospectus Supplement and legal opinion from Arendt & Medernach SA relating to the validity of the securities to

STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...

As today marks the beginning of a new board service calendar year and in accordance with the Remuneration policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, today four independent board directors received a stock option grant allow

The 2024 Annual and Extraordinary General Meeting (the "2024 AGM") of Alvotech (the "Company") was held on June 7, 2024, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...